Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

por du Rusquec, P., Guimbaud, R., Le Malicot, K., Gornet, J.-M., Nguyen, S., Lecomte, T., Khemissa-Akouz, F., Perrier, H., Bouché, O., Paoletti, X., Le Tourneau, C.
Publicado 2023

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

por Aparicio, T, Bouché, O, Taieb, J, Maillard, E, Kirscher, S, Etienne, P -L, Faroux, R, Khemissa Akouz, F, El Hajbi, F, Locher, C, Rinaldi, Y, Lecomte, T, Lavau-Denes, S, Baconnier, M, Oden-Gangloff, A, Genet, D, Paillaud, E, Retornaz, F, François, E, Bedenne, L
Publicado 2018